Stock analysts at Jefferies Financial Group initiated coverage on shares of Vicore Pharma (NASDAQ:VCRE – Get Free Report) in a research note issued on Friday, Benzinga reports. The firm set a “buy” rating and a $25.00 price target on the stock. Jefferies Financial Group’s target price indicates a potential upside of 183.45% from the company’s previous close.
Vicore Pharma Stock Up 1.8%
NASDAQ:VCRE traded up $0.16 during trading hours on Friday, reaching $8.82. The company had a trading volume of 21,078 shares.
About Vicore Pharma
Vicore Pharma is a Swedish clinical-stage biotechnology company focused on developing medicines for severe respiratory diseases. The company’s research is based largely on therapies designed to activate the angiotensin II type 2 receptor, a pathway that may help counteract inflammation, fibrosis and tissue damage.
Vicore’s lead product candidate is buloxibutid, also known as C21, an oral investigational therapy being developed primarily for idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring of lung tissue.
See Also
- Five stocks we like better than Vicore Pharma
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Vicore Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicore Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
